GENEMATRIX INC.

109820KOSDAQResearch and development

GENEMATRIX INC. (109820, KOSDAQ) reported KRW 11bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202310-3-13123Separate
202410-2-42819Separate
202511-1-22717Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-26%-9.1%73.8%-3.9%
2024-16.4%-37.4%67.6%-19.5%
2025-6.4%-17.2%64.1%-10.5%

Revenue moved 8.4% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 32bn
Close priceKRW 1,582
Listed shares20,393,640
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)69
Women36 (52.2%)
Average tenure4.2 years
Annual pay, menKRW 52,084,576
Annual pay, womenKRW 42,866,333
Pay ratio, women to men82.3%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →